Swansea University, College of Medicine, presents scientific poster at IDF 2013
Quo-Lab delivers lab-accurate results from 4µL venous or finger prick blood sample For a high resolution image please contact firstname.lastname@example.org
Cardiff, UK – 3nd December 2013 – EKF Diagnostics, the global diagnostics business, announces the successful assessment of its Quo-Test and Quo-Lab point-of-care HbA1c analyzers within the College of Medicine, Swansea University. Dr Stephen Luzio, Associate Professor at the University, will give a scientific poster presentation entitled ‘Assessment of two point-of-care analyzers for the determination of HbA1c’ at the World Diabetes Congress – International Diabetes Federation (IDF) 2013, Melbourne, Australia, 2nd to 6th December.
Glycated hemoglobin (HbA1c) is widely used as a means of monitoring diabetes control and has recently been recommended for use as a method of diabetes diagnosis. Measurement of HbA1c with point-of-care analyzers (POCT) has the advantage that samples can be determined on site, while a patient is still in the clinic. Dr Luzio and his team have successfully compared EKF’s Quo-Test and Quo-Lab POCT HbA1c analyzers with an established laboratory HPLC method (D10, Biorad).
Dr Luzio’s scientific poster concludes that, “Use of the Quo-Test and Quo-Lab HbA1c POCT analyzers, provides a rapid, accurate and reproducible method of determination of HbA1c, with results comparable to an established laboratory HPLC method. Both have the benefit of being able to generate results immediately in the clinical setting, providing greater convenience to the patient.”
Also at IDF 2013, EKF Diagnostics will showcase its Quo-Lab and Quo-Test HbA1c analyzers, as well as the Biosen C-Line glucose and lactate analyzer at Stand A15. Both Quo-Test and Quo-Lab use boronate fluorescence quenching technology to measure HbA1c from just 4 µL of capillary or venous blood and deliver results within 4 minutes. The Biosen C-Line analyzer is used to measure glucose and lactate precisely and quickly, from 25 seconds, in clinics, laboratories and sports medicine facilities around the world.
The aim of IDF is to advance diabetes care and prevention, and to establish a cure worldwide. IDF organizes the World Diabetes Congress on a biennial basis in differing global locations, to uniquely bring together healthcare professionals, researchers, policy makers, and people with diabetes, their carers and families. Dr Luzio is also Portfolio Development Manager at the Diabetes Research Network which aims to promote existing strengths and potential in diabetes research and diabetes care in Wales.
For more information on EKF Diagnostics, please visit www.ekfdiagnostics.com.
About EKF Diagnosticswww.ekfdiagnostics.com
EKF Diagnostics Holdings plc specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics.
Point-of-care diagnostics: EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to liquid reagent manufacture, design and building of world-class diagnostic devices, and distribution of rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Companion Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics - EKF Molecular Diagnostics develops technologies for cancer gene detection. Through its acquisition of UK-based 360 Genomics and by offering innovative products with the potential to change current DNA extraction and detection practices, EKF is addressing the fast growing companion diagnostics market.
EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.